Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial

Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, Arlene O. Siefker-Radtke, Jakub Zolnierek, Tibor Csoszi, Sang Joon Shin, Se Hoon Park, Vagif Atduev, Mahmut Gumus, Yu Li Su, Saziye Burcak Karaca, Hernán Javier Cutuli, Mehmet A.N. Sendur, Liji Shen, Karen O'Hara, Chinyere E. Okpara, Sonia Franco, Blanca Homet Moreno, Petros GrivasYohann Loriot

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences